Successful Use of Apixaban for Paget-Schroetter Syndrome in a Pediatric Patient

• Published in: The journal of pediatric pharmacology and therapeutics Vol. 26; no. 5; pp. 508 - 511
• Main Authors: Manis, Melanie M., Cummins, Lauren E., Kyle, Jeffrey A., Taylor, Steven M.
• Format: Journal Article
• Language: English
• Published: Pediatric Pharmacy Advocacy Group 2021
• Subjects: Clinical Vignette
• ISSN: 1551-6776; 2331-348X
• DOI: 10.5863/1551-6776-26.5.508

Paget-Schroetter syndrome (PSS) is a rare syndrome that typically develops in young, healthy males subjected to repetitive overhead motions resulting in compression and thrombosis of the subclavian vein. This “effort thrombosis” typically occurs acutely in patients with specific anatomic variations within the thoracic outlet and is treated by a combination of surgical and pharmacologic interventions. There is a paucity of literature regarding this syndrome, particularly surrounding pharmacotherapy, and in the treatment of pediatric patients. This case report documents the pharmacologic treatment of a 17-year-old, male, baseball player with confirmed PSS. Apixaban was selected as the anticoagulant therapy of choice following the determination of its safety and anticipated efficacy for this pediatric patient. Upon admission, anticoagulation was initiated with intravenous heparin and transitioned to warfarin for 1 dose. On day 2, the patient was discharged with apixaban 10 mg twice daily for 7 days, followed by 5 mg twice daily. One week later, he underwent catheter-directed thrombectomy, followed by thoracic outlet decompression with resection of the first rib. Apixaban therapy was continued for 10 weeks after the procedure to diminish the risk of any further thrombotic events. This pediatric patient with PSS was successfully treated with apixaban in conjunction with surgical management. Treatment with apixaban resulted in continued resolution of thrombus after follow-up, with no complications reported thereafter. Further research is needed to definitively determine the safety and efficacy of apixaban for the use of pediatric anticoagulation, particularly in upper extremity deep vein thrombosis.